Abstract
Sleep deficiency and undiagnosed or untreated sleep disorders are pervasive among employed adults, yet often ignored in the context of workplace health promotion programs among employers. Smartphone applications (app) are a promising, scalable approach to improving sleep among employees. In this randomized clinical trial, we evaluate the dayzz app, a personalized sleep training program that promotes healthy sleep and sleep disorders awareness through personalized, comprehensive sleep improvement solutions. In a sample of daytime employees affiliated with a large healthcare organization, we evaluated the dayzz app in a parallel-group, randomized, waitlist control trial. Participants were randomly assigned to either use the dayzz app throughout the study or the waitlist control condition where they would receive the dayzz app at the end of the study period. We collected data on employee sleep (e.g., sleep duration, sleep health behavioral changes); workplace outcomes (e.g., employee presenteeism, absenteeism, and performance); and healthcare utilization (e.g., mental health, ambulatory visits, and emergency room visits), throughout the study. Results show that those assigned to the experimental condition exhibited an increase in healthy sleep behaviors; an increase in sleep duration; a trend toward a more regular sleep schedule; and a significant increase in overall sleep quality. Regarding workplace outcomes, results showed that those in the experimental condition also demonstrated a trend toward less absenteeism and significantly lower presenteeism; and those in the experimental condition reported lower healthcare utilization. Results from this randomized clinical trial demonstrate that a workplace sleep wellness program can be beneficial to both the employee and employer.
Competing Interest Statement
Dr. Robbins has received consulting fees from Denihan Hospitality; Sleep Cycle AB; With Deep, Inc., Wave Meditation, Inc., Savoir Beds Ltd., Loona Inc., and Rituals Cosmetics. Dr. Weaver reports consulting fees from the National Sleep Foundation and the University of Pittsburgh. Dr. Barger reports consulting fees from Puget Sound Pilots and Boston Childrens Hospital. Dr. Weaver reports personal fees from the University of Pittsburgh and the National Sleep Foundation. Dr. Quan has served as a consultant for Best Doctors, Jazz Pharmaceuticals and Whispersom. Dr. Barger reports personal fees from the University of Pittsburgh, CurAegis, Casis, Puget Sound Pilots, and Boston Childrens Hospital. Dr. Czeisler is/was a paid consultant to or speaker for Ganesco, Inc., Institute of Digital Media and Child Development, Klarman Family Foundation, M. Davis and Co, Physicians Seal, Samsung, State of Washington Board of Pilotage Commissioners, Tencent Holdings Ltd, Teva Pharma Australia, and Vanda Pharmaceuticals Inc, in which Dr. Czeisler holds an equity interest; received travel support from Aspen Brain Institute, Bloomage International Investment Group, Inc., UK Biotechnology and Biological Sciences Research Council, Bouley Botanicals, Dr. Stanley Ho Medical Development Foundation, Illuminating Engineering Society, National Safety Council, Tencent Holdings Ltd, and The Wonderful Company; receives research/education support through BWH from Cephalon, Mary Ann & Stanley Snider via Combined Jewish Philanthropies, Harmony Biosciences LLC, Jazz Pharmaceuticals PLC Inc, Johnson & Johnson, NeuroCare, Inc., Philips Respironics Inc/Philips Homecare Solutions, Regeneron Pharmaceuticals, Regional Home Care, Teva Pharmaceuticals Industries Ltd, Sanofi SA, Optum, ResMed, San Francisco Bar Pilots, Sanofi, Schneider, Simmons, Sysco, Philips, Vanda Pharmaceuticals; is/was an expert witness in legal cases, including those involving Advanced Power Technologies, Aegis Chemical Solutions LLC, Amtrak; Casper Sleep Inc, C&J Energy Services, Complete General Construction Co, Dallas Police Association, Enterprise Rent-A-Car, Steel Warehouse, FedEx, Greyhound Lines, Palomar Health District, PAR Electrical Contractors, Product & Logistics Services LLC, Puckett Emergency Medical Services LLC, South Carolina Central Railroad Company LLC, Union Pacific Railroad, UPS, and Vanda Pharmaceuticals; serves as the incumbent of an endowed professorship provided to Harvard University by Cephalon, Inc.; and receives royalties from McGraw Hill, and Philips Respironics for the Actiwatch-2 and Actiwatch Spectrum devices. These interests are managed and reviewed for Dr. Czeisler by the BWH Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. Copyright: 2000-2020 Charles A. Czeisler and BWH.
Clinical Trial
NCT04224285
Clinical Protocols
Funding Statement
This study was funded by dayzz Live Well Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Partners Healthcare Institutional Review Board gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
ClinicalTrials.gov Identifier: NCT04224285
Ethics Approval: The Partners Healthcare Institutional Review Board gave ethical approval for this work.
Funding Statement: This study was funded by dayzz Live Well Ltd.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
